CA2121599A1 - Monoclonal antibodies directed against the microtubule-associated protein tau - Google Patents

Monoclonal antibodies directed against the microtubule-associated protein tau

Info

Publication number
CA2121599A1
CA2121599A1 CA002121599A CA2121599A CA2121599A1 CA 2121599 A1 CA2121599 A1 CA 2121599A1 CA 002121599 A CA002121599 A CA 002121599A CA 2121599 A CA2121599 A CA 2121599A CA 2121599 A1 CA2121599 A1 CA 2121599A1
Authority
CA
Canada
Prior art keywords
microtubule
monoclonal antibodies
directed against
antibodies directed
associated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002121599A
Other languages
French (fr)
Other versions
CA2121599C (en
Inventor
Marc Mercken
Eva-Maria Mandelkow
Marc Vandermeeren
Eugeen Vanmechelen
Andre Van De Voorde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Marc Mercken
Eva-Maria Mandelkow
Marc Vandermeeren
Eugeen Vanmechelen
Andre Van De Voorde
N.V. Innogenetics S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Van De Voorde, N.V. Innogenetics S.A. filed Critical Marc Mercken
Publication of CA2121599A1 publication Critical patent/CA2121599A1/en
Application granted granted Critical
Publication of CA2121599C publication Critical patent/CA2121599C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
CA002121599A 1991-10-25 1992-10-17 Monoclonal antibodies directed against the microtubule-associated protein tau Expired - Lifetime CA2121599C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP91402871.7 1991-10-25
EP91402871 1991-10-25
PCT/EP1992/002392 WO1993008302A1 (en) 1991-10-25 1992-10-17 Monoclonal antibodies directed against the microtubule-associated protein tau

Publications (2)

Publication Number Publication Date
CA2121599A1 true CA2121599A1 (en) 1993-04-29
CA2121599C CA2121599C (en) 2007-04-10

Family

ID=8208630

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002121599A Expired - Lifetime CA2121599C (en) 1991-10-25 1992-10-17 Monoclonal antibodies directed against the microtubule-associated protein tau

Country Status (10)

Country Link
US (4) US6238892B1 (en)
EP (1) EP0610330B1 (en)
JP (2) JP3909084B2 (en)
AT (1) ATE154642T1 (en)
AU (1) AU662178B2 (en)
CA (1) CA2121599C (en)
DE (1) DE69220503T2 (en)
DK (1) DK0610330T3 (en)
GR (1) GR3024635T3 (en)
WO (1) WO1993008302A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
JP3909084B2 (en) * 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム Monoclonal antibody against microtubule-associated protein tau
JPH06239899A (en) * 1993-02-12 1994-08-30 Teijin Ltd Antibody for human tau protein and determination of human tau protein in body fluid utilizing the same
EP0737208B1 (en) * 1993-12-21 2006-08-02 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
AU710952B2 (en) * 1994-07-29 1999-09-30 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
JP3671440B2 (en) 1994-09-16 2005-07-13 株式会社デンソー Torque transmission device
US6215892B1 (en) * 1995-11-30 2001-04-10 Chromavision Medical Systems, Inc. Method and apparatus for automated image analysis of biological specimens
US6718053B1 (en) * 1996-11-27 2004-04-06 Chromavision Medical Systems, Inc. Method and apparatus for automated image analysis of biological specimens
US20050084875A1 (en) * 1997-10-24 2005-04-21 University Of Rochester Molecular markers for the diagnosis of Alzheimer's disease
US20020102553A1 (en) * 1997-10-24 2002-08-01 University Of Rochester Molecular markers for the diagnosis of alzheimer's disease
US6797478B1 (en) * 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
CA2340433A1 (en) * 1998-09-08 2000-03-16 Innogenetics N.V. Tau as a marker for early cns damage
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
WO2003042788A2 (en) * 2001-11-13 2003-05-22 Chromavision Medical Systems, Inc. A system for tracking biological samples
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
CA2483635A1 (en) * 2002-04-25 2003-11-06 Alon Shalev Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US7272252B2 (en) * 2002-06-12 2007-09-18 Clarient, Inc. Automated system for combining bright field and fluorescent microscopy
US20050037406A1 (en) * 2002-06-12 2005-02-17 De La Torre-Bueno Jose Methods and apparatus for analysis of a biological specimen
JP2006515999A (en) * 2002-11-14 2006-06-15 ブレインズゲート リミティド Surgical tools and techniques for stimulation
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US20040202357A1 (en) 2003-04-11 2004-10-14 Perz Cynthia B. Silhouette image acquisition
WO2005080986A1 (en) * 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US7653260B2 (en) * 2004-06-17 2010-01-26 Carl Zeis MicroImaging GmbH System and method of registering field of view
US8582924B2 (en) * 2004-06-30 2013-11-12 Carl Zeiss Microimaging Gmbh Data structure of an image storage and retrieval system
WO2006021957A2 (en) * 2004-08-23 2006-03-02 Brainsgate Ltd. Concurrent bilateral spg modulation
US20070031043A1 (en) * 2005-08-02 2007-02-08 Perz Cynthia B System for and method of intelligently directed segmentation analysis for automated microscope systems
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR101439828B1 (en) 2005-11-30 2014-09-17 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
WO2009106081A1 (en) 2008-02-29 2009-09-03 Dako Denmark A/S Systems and methods for tracking and providing workflow information
CA3120504A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
EP2480891B1 (en) * 2009-09-24 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
WO2011053565A2 (en) * 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
US9012237B2 (en) 2009-11-17 2015-04-21 Servicios Cientificos Neuroinnovation Limitada Innovative blood platelets biomarker for early diagnosis of alzheimer's disease
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
JP2014503178A (en) 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー Human anti-tau antibody
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
JP6306513B2 (en) * 2011-12-20 2018-04-04 ヤンセン バイオテツク，インコーポレーテツド Anti-PHF-tau antibody and use thereof
CN104781278B (en) 2012-07-03 2018-06-12 华盛顿大学 For the antibody of TAU
MX359817B (en) 2012-08-16 2018-10-11 Ipierian Inc Methods of treating a tauopathy.
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
EA035932B1 (en) 2012-12-21 2020-09-02 Байоджен Ма Инк. Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
TWI664190B (en) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 Humanized anti-tau antibodies
DE102014013571A1 (en) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoclonal antibody to human TAU protein
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
MA41669A1 (en) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Antibodies binding to tau
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JOP20180021A1 (en) 2017-03-16 2019-01-30 Janssen Biotech Inc Anti-phf-tau antibodies and uses thereof
WO2019118906A2 (en) * 2017-12-14 2019-06-20 University Of Florida Research Foundation Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
WO2022144406A1 (en) 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US5733734A (en) * 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
JP3909084B2 (en) 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム Monoclonal antibody against microtubule-associated protein tau
US5843779A (en) * 1992-12-14 1998-12-01 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies
EP0737208B1 (en) * 1993-12-21 2006-08-02 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications

Also Published As

Publication number Publication date
DE69220503D1 (en) 1997-07-24
US20110143443A9 (en) 2011-06-16
EP0610330B1 (en) 1997-06-18
AU2800292A (en) 1993-05-21
US20090137051A1 (en) 2009-05-28
US20010018191A1 (en) 2001-08-30
US6238892B1 (en) 2001-05-29
GR3024635T3 (en) 1997-12-31
ATE154642T1 (en) 1997-07-15
US20060008853A1 (en) 2006-01-12
US6900293B2 (en) 2005-05-31
CA2121599C (en) 2007-04-10
US8163873B2 (en) 2012-04-24
JP2004043487A (en) 2004-02-12
JPH07502888A (en) 1995-03-30
DK0610330T3 (en) 1998-01-26
WO1993008302A1 (en) 1993-04-29
JP3909084B2 (en) 2007-04-25
AU662178B2 (en) 1995-08-24
EP0610330A1 (en) 1994-08-17
DE69220503T2 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
CA2121599A1 (en) Monoclonal antibodies directed against the microtubule-associated protein tau
EP0394946A3 (en) Human monoclonal antibody, and its production and use
DK0673418T3 (en) Monoclonal antibodies directed against microtubule-associated tau protein, hybridomas secreting these antibodies, antigen
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
AU2097692A (en) Method for the production of monoclonal antibodies utilizing a germfree animal
AU3287989A (en) Antibodies to a4 amyloid peptide
CA2212150A1 (en) Monoclonal antibodies for human osteogenic cell surface antigens
GR3025630T3 (en) Monoclonal antibody against human IgE
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
NO972522L (en) Monoclonal antibodies with immunosuppressive activity
PL314414A1 (en) Antiidiotypic antibodies capable to induce an immunological response in respect to the receptor of epidermis growth factor
AU2070688A (en) Antigen recognized by mca 16-88
EP0537168A4 (en) Ctaa 28a32, the antigen recognized by mca 28a32
CA2150816A1 (en) Monoclonal antibodies directed against the microtubule- associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and theirapplications
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
WO2001032692A3 (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
GR3007245T3 (en)
WO1998027999A3 (en) Anti-allergenic compounds for the treatment of immune diseases containing haptenized antigen antibody complexes
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
CA2151945A1 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis
Predy Characterization of novel antigens, detected using monoclonal antibodies raised against tissue from the central nervous system of multiple sclerosis patients
Vlasenko et al. Regulation of immunoglobulin production by myelopide in peripheral blood lymphocyte culture from normal individuals and pattents with a secondary immunodeficiency state
Menon et al. Specificity of the antibody response in the autoimmune-mediated demyelinating pathway
Ritter et al. Immunogenicity of bovine brain gangliosides in Lewis rats with ean
EP0332421A3 (en) Monoclonal antibodies recognizing human psti, hybridomas producing the same, and their preparation and use

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry
MKEX Expiry

Effective date: 20121017